[Form 4] Tarsus Pharmaceuticals, Inc. Insider Trading Activity
Form 4 highlights for Tarsus Pharmaceuticals (TARS): CFO & Chief Strategy Officer Jeffrey S. Farrow reported the settlement of 27,881 restricted stock units (RSUs) on 16-Jun-2025, converting them into an equal number of common shares (Code M). The following day, 13,608 shares were sold at $40.42 per share (Code S) via a mandatory 鈥渟ell-to-cover鈥� transaction to satisfy tax-withholding requirements. After these transactions, Farrow directly owns 36,704 common shares and continues to hold 55,763 unvested/undelivered RSUs granted under the 2020 Stock Plan. The reported sale was non-discretionary and does not indicate a change in the insider鈥檚 investment outlook. No other derivative activity, option exercises, or discretionary open-market sales were disclosed.
Principali informazioni dal Modulo 4 per Tarsus Pharmaceuticals (TARS): Il CFO e Chief Strategy Officer Jeffrey S. Farrow ha comunicato la liquidazione di 27.881 unit脿 azionarie vincolate (RSU) il 16 giugno 2025, convertendole in un numero pari di azioni ordinarie (Codice M). Il giorno seguente, 13.608 azioni sono state vendute a 40,42$ ciascuna (Codice S) tramite una transazione obbligatoria di 鈥渧endita per copertura鈥� per soddisfare gli obblighi fiscali. Dopo queste operazioni, Farrow detiene direttamente 36.704 azioni ordinarie e continua a possedere 55.763 RSU non maturate/non consegnate concesse nell鈥檃mbito del Piano Azionario 2020. La vendita comunicata 猫 stata non discrezionale e non indica un cambiamento nella prospettiva di investimento dell鈥檌nsider. Non sono state segnalate altre attivit脿 su derivati, esercizi di opzioni o vendite discrezionali sul mercato aperto.
Aspectos destacados del Formulario 4 para Tarsus Pharmaceuticals (TARS): El CFO y Director de Estrategia Jeffrey S. Farrow inform贸 la liquidaci贸n de 27,881 unidades restringidas de acciones (RSUs) el 16 de junio de 2025, convirti茅ndolas en un n煤mero equivalente de acciones comunes (C贸digo M). Al d铆a siguiente, se vendieron 13,608 acciones a 40.42$ por acci贸n (C贸digo S) mediante una transacci贸n obligatoria de 鈥渧enta para cubrir鈥� para cumplir con los requisitos de retenci贸n fiscal. Tras estas transacciones, Farrow posee directamente 36,704 acciones comunes y mantiene 55,763 RSUs no devengadas/no entregadas otorgadas bajo el Plan de Acciones 2020. La venta reportada fue no discrecional y no indica un cambio en la perspectiva de inversi贸n del insider. No se divulgaron otras actividades con derivados, ejercicios de opciones o ventas discrecionales en el mercado abierto.
Tarsus Pharmaceuticals(TARS)鞚� Form 4 欤检殧 雮挫毄: CFO 瓴� 斓滉碃鞝勲灥毂呾瀯鞛�(Chief Strategy Officer) Jeffrey S. Farrow電� 2025雲� 6鞗� 16鞚检棎 27,881臧滌潣 鞝滍暅欤检嫕雼渼(RSU)毳� 鞝曥偘頃橃棳 霃欖澕頃� 靾橃潣 氤错喌欤茧 鞝勴櫂頃橃榾雼り碃 氤搓碃頄堨姷雼堧嫟(Code M). 雼れ潓 雮�, 13,608欤茧ゼ 欤茧嫻 40.42雼煬鞐� 毵る弰頃橂姅 鞚橂鞝� '靹戈笀 雮╇秬毳� 鞙勴暅 毵る弰' 瓯半灅臧� 鞚措（鞏挫鞀惦媹雼�(Code S). 鞚� 瓯半灅 鞚错泟 Farrow電� 歆侅爲 36,704欤检潣 氤错喌欤�毳� 氤挫湢頃橁碃 鞛堨溂氅�, 2020雲� 欤检嫕 瓿勴殟鞐� 霐半澕 攵�鞐悳 55,763臧滌潣 氙疙檿鞝�/氙胳旮� RSU霃� 瓿勳啀 氤挫湢 欷戩瀰雼堧嫟. 氤搓碃霅� 毵る弰電� 牍勋灛霟夓爜鞚措┌ 雮措秬鞛愳潣 韴瀽 鞝勲 氤�頇旊姅 雮橅儉雮挫 鞎婌姷雼堧嫟. 旮绊儉 韺岇儩靸來拡 頇滊彊, 鞓奠厴 頄夓偓 霕愲姅 鞛焿鞝� 瓿店皽鞁滌灔 毵る弰電� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.
Points cl茅s du Formulaire 4 pour Tarsus Pharmaceuticals (TARS) : Le CFO et Chief Strategy Officer Jeffrey S. Farrow a d茅clar茅 le r猫glement de 27 881 unit茅s d鈥檃ctions restreintes (RSU) le 16 juin 2025, les convertissant en un nombre 茅gal d鈥檃ctions ordinaires (Code M). Le lendemain, 13 608 actions ont 茅t茅 vendues 脿 40,42 $ chacune (Code S) via une transaction obligatoire de 芦 vente pour couvrir 禄 afin de satisfaire aux exigences de retenue fiscale. Apr猫s ces transactions, Farrow d茅tient directement 36 704 actions ordinaires et continue de d茅tenir 55 763 RSU non acquises/non livr茅es attribu茅es dans le cadre du Plan d鈥橝ctions 2020. La vente rapport茅e 茅tait non discr茅tionnaire et n鈥檌ndique pas de changement dans la perspective d鈥檌nvestissement de l鈥檌niti茅. Aucune autre activit茅 sur d茅riv茅s, exercice d鈥檕ptions ou vente discr茅tionnaire sur le march茅 ouvert n鈥檃 茅t茅 divulgu茅e.
Form 4 Highlights f眉r Tarsus Pharmaceuticals (TARS): CFO und Chief Strategy Officer Jeffrey S. Farrow meldete die Abrechnung von 27.881 Restricted Stock Units (RSUs) am 16. Juni 2025, die in eine gleiche Anzahl von Stammaktien umgewandelt wurden (Code M). Am folgenden Tag wurden 13.608 Aktien zu je 40,42 $ im Rahmen einer verpflichtenden 鈥濻ell-to-Cover鈥�-Transaktion verkauft, um die Steuerabzugsverpflichtungen zu erf眉llen (Code S). Nach diesen Transaktionen besitzt Farrow direkt 36.704 Stammaktien und h盲lt weiterhin 55.763 unverfallene/nicht ausgelieferte RSUs, die im Rahmen des Aktienplans von 2020 gew盲hrt wurden. Der gemeldete Verkauf war nicht diskretion盲r und deutet nicht auf eine 脛nderung der Investitionsperspektive des Insiders hin. Keine weiteren Derivataktivit盲ten, Optionsaus眉bungen oder diskretion盲ren Verk盲ufe am offenen Markt wurden offengelegt.
- None.
- None.
Insights
TL;DR: Routine RSU vesting; tax-related sale, minimal market impact.
The filing documents a standard vesting event for 27,881 RSUs granted in 2023. The insider鈥檚 subsequent sale of 13,608 shares鈥攔oughly 49% of the shares received鈥攚as an automatic, issuer-directed action to cover withholding taxes, limiting informational value regarding the executive鈥檚 sentiment. Post-transaction ownership remains meaningful at 36,704 shares plus 55,763 RSUs, indicating continued alignment with shareholders. Given Tarsus鈥� ~27 million shares outstanding, the net share sale represents <0.05% of float and should not materially influence supply-demand dynamics or valuation. Overall, the filing is neutral for investors.
Principali informazioni dal Modulo 4 per Tarsus Pharmaceuticals (TARS): Il CFO e Chief Strategy Officer Jeffrey S. Farrow ha comunicato la liquidazione di 27.881 unit脿 azionarie vincolate (RSU) il 16 giugno 2025, convertendole in un numero pari di azioni ordinarie (Codice M). Il giorno seguente, 13.608 azioni sono state vendute a 40,42$ ciascuna (Codice S) tramite una transazione obbligatoria di 鈥渧endita per copertura鈥� per soddisfare gli obblighi fiscali. Dopo queste operazioni, Farrow detiene direttamente 36.704 azioni ordinarie e continua a possedere 55.763 RSU non maturate/non consegnate concesse nell鈥檃mbito del Piano Azionario 2020. La vendita comunicata 猫 stata non discrezionale e non indica un cambiamento nella prospettiva di investimento dell鈥檌nsider. Non sono state segnalate altre attivit脿 su derivati, esercizi di opzioni o vendite discrezionali sul mercato aperto.
Aspectos destacados del Formulario 4 para Tarsus Pharmaceuticals (TARS): El CFO y Director de Estrategia Jeffrey S. Farrow inform贸 la liquidaci贸n de 27,881 unidades restringidas de acciones (RSUs) el 16 de junio de 2025, convirti茅ndolas en un n煤mero equivalente de acciones comunes (C贸digo M). Al d铆a siguiente, se vendieron 13,608 acciones a 40.42$ por acci贸n (C贸digo S) mediante una transacci贸n obligatoria de 鈥渧enta para cubrir鈥� para cumplir con los requisitos de retenci贸n fiscal. Tras estas transacciones, Farrow posee directamente 36,704 acciones comunes y mantiene 55,763 RSUs no devengadas/no entregadas otorgadas bajo el Plan de Acciones 2020. La venta reportada fue no discrecional y no indica un cambio en la perspectiva de inversi贸n del insider. No se divulgaron otras actividades con derivados, ejercicios de opciones o ventas discrecionales en el mercado abierto.
Tarsus Pharmaceuticals(TARS)鞚� Form 4 欤检殧 雮挫毄: CFO 瓴� 斓滉碃鞝勲灥毂呾瀯鞛�(Chief Strategy Officer) Jeffrey S. Farrow電� 2025雲� 6鞗� 16鞚检棎 27,881臧滌潣 鞝滍暅欤检嫕雼渼(RSU)毳� 鞝曥偘頃橃棳 霃欖澕頃� 靾橃潣 氤错喌欤茧 鞝勴櫂頃橃榾雼り碃 氤搓碃頄堨姷雼堧嫟(Code M). 雼れ潓 雮�, 13,608欤茧ゼ 欤茧嫻 40.42雼煬鞐� 毵る弰頃橂姅 鞚橂鞝� '靹戈笀 雮╇秬毳� 鞙勴暅 毵る弰' 瓯半灅臧� 鞚措（鞏挫鞀惦媹雼�(Code S). 鞚� 瓯半灅 鞚错泟 Farrow電� 歆侅爲 36,704欤检潣 氤错喌欤�毳� 氤挫湢頃橁碃 鞛堨溂氅�, 2020雲� 欤检嫕 瓿勴殟鞐� 霐半澕 攵�鞐悳 55,763臧滌潣 氙疙檿鞝�/氙胳旮� RSU霃� 瓿勳啀 氤挫湢 欷戩瀰雼堧嫟. 氤搓碃霅� 毵る弰電� 牍勋灛霟夓爜鞚措┌ 雮措秬鞛愳潣 韴瀽 鞝勲 氤�頇旊姅 雮橅儉雮挫 鞎婌姷雼堧嫟. 旮绊儉 韺岇儩靸來拡 頇滊彊, 鞓奠厴 頄夓偓 霕愲姅 鞛焿鞝� 瓿店皽鞁滌灔 毵る弰電� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.
Points cl茅s du Formulaire 4 pour Tarsus Pharmaceuticals (TARS) : Le CFO et Chief Strategy Officer Jeffrey S. Farrow a d茅clar茅 le r猫glement de 27 881 unit茅s d鈥檃ctions restreintes (RSU) le 16 juin 2025, les convertissant en un nombre 茅gal d鈥檃ctions ordinaires (Code M). Le lendemain, 13 608 actions ont 茅t茅 vendues 脿 40,42 $ chacune (Code S) via une transaction obligatoire de 芦 vente pour couvrir 禄 afin de satisfaire aux exigences de retenue fiscale. Apr猫s ces transactions, Farrow d茅tient directement 36 704 actions ordinaires et continue de d茅tenir 55 763 RSU non acquises/non livr茅es attribu茅es dans le cadre du Plan d鈥橝ctions 2020. La vente rapport茅e 茅tait non discr茅tionnaire et n鈥檌ndique pas de changement dans la perspective d鈥檌nvestissement de l鈥檌niti茅. Aucune autre activit茅 sur d茅riv茅s, exercice d鈥檕ptions ou vente discr茅tionnaire sur le march茅 ouvert n鈥檃 茅t茅 divulgu茅e.
Form 4 Highlights f眉r Tarsus Pharmaceuticals (TARS): CFO und Chief Strategy Officer Jeffrey S. Farrow meldete die Abrechnung von 27.881 Restricted Stock Units (RSUs) am 16. Juni 2025, die in eine gleiche Anzahl von Stammaktien umgewandelt wurden (Code M). Am folgenden Tag wurden 13.608 Aktien zu je 40,42 $ im Rahmen einer verpflichtenden 鈥濻ell-to-Cover鈥�-Transaktion verkauft, um die Steuerabzugsverpflichtungen zu erf眉llen (Code S). Nach diesen Transaktionen besitzt Farrow direkt 36.704 Stammaktien und h盲lt weiterhin 55.763 unverfallene/nicht ausgelieferte RSUs, die im Rahmen des Aktienplans von 2020 gew盲hrt wurden. Der gemeldete Verkauf war nicht diskretion盲r und deutet nicht auf eine 脛nderung der Investitionsperspektive des Insiders hin. Keine weiteren Derivataktivit盲ten, Optionsaus眉bungen oder diskretion盲ren Verk盲ufe am offenen Markt wurden offengelegt.
FAQ
How many TARS shares did CFO Jeffrey Farrow acquire and sell?
What price were the TARS shares sold at in the Form 4?
Was the insider sale discretionary?
How many TARS shares does the CFO still own after the transactions?
Do these transactions materially affect Tarsus Pharmaceuticals鈥� share count?
